Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV

Drug and Alcohol Dependence

Volumn 100, Issue 1-2, 2009, Pages 115-121

  Barnett, Paul G ^a   Sorensen, James L ^b   Wong, Wynnie ^b   Haug, Nancy A ^b   Hall, Sharon M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti HIV agents therapeutic use; Health care costs; Methadone; Opioid related disorders; Patient compliance

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; METHADONE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MONEY; MOTIVATION; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; DELIVERY OF HEALTH CARE; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; METHADONE; MIDDLE AGED; MOTIVATION; OPIOID-RELATED DISORDERS;

EID: 57649236194     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.09.017     Document Type: Article

References (49)

1. Bangsberg D.R., Hecht F.M., Charlebois E.D., Zolopa A.R., Holodniy M., Sheiner L., Bamberger J.D., Chesney M.A., and Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14 (2000) 357-366
2. Bangsberg D.R., Moss A.R., and Deeks S.G. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J. Antimicrob. Chemother. 53 (2004) 696-699
3. Bangsberg D.R., Perry S., Charlebois E.D., Clark R.A., Roberston M., Zolopa A.R., and Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15 (2001) 1181-1183
4. Barnett P.G., and Garber A.M. The cost of VA-sponsored research. Acad. Med. 71 (1996) 1074-1078
5. Bozzette S.A., and Gifford A.L. The economic viability of antiretroviral adherence interventions. Am. J. Med. 115 (2003) 672-673
6. Calsyn D.A., Wells E.A., Saxon A.J., Jackson T.R., Wrede A.F., Stanton V., and Fleming C. Contingency management of urinalysis results and intensity of counseling services have an interactive impact on methadone maintenance treatment outcome. J. Addict. Dis. 13 (1994) 47-63
7. Celentano D.D., Galai N., Sethi A.K., Shah N.G., Strathdee S.A., Vlahov D., and Gallant J.E. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 15 (2001) 1707-1715
8. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 17 (2003) 169-177
9. Cohen H.E. Drugs Topic Red Book (2003), Thomson PDR, Montvale NJ
10. Collier A.C., Ribaudo H., Mukherjee A.L., Feinberg J., Fischl M.A., and Chesney M. A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. J. Infect. Dis. 192 (2005) 1398-1406
11. Elk R., Grabowski J., Rhoades H., Spiga R., Schmitz J., and Jennings W. Compliance with tuberculosis treatment in methadone-maintained patients: behavioral interventions. J. Subst. Abuse Treat. 10 (1993) 371-382
12. Freedberg K.A., Losina E., Weinstein M.C., Paltiel A.D., Cohen C.J., Seage G.R., Craven D.E., Zhang H., Kimmel A.D., and Goldie S.J. The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344 (2001) 824-831
13. Gifford A.L., Bormann J.E., Shively M.J., Wright B.C., Richman D.D., and Bozzette S.A. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acq. Immune Def. Synd. 23 (2000) 386-395
14. Goldie S.J., Paltiel A.D., Weinstein M.C., Losina E., Seage III G.R., Kimmel A.D., Walensky R.P., Sax P.E., and Freedberg K.A. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am. J. Med. 115 (2003) 632-641
15. Gross R., Bilker W.B., Friedman H.M., and Strom B.L. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 15 (2001) 2109-2117
16. Hall S.M., Cooper J.L., Burmaster S., and Polk A. Contingency contracting as a therapeutic tool with methadone maintenance clients: six single subject studies. Behav. Res. Ther. 15 (1977) 438-441
17. Haynes R. Brian, Ackloo Elizabeth, Sahota Navdeep, McDonald Heather Pauline, Yao Xiaomei. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews. 2008 Issue 2 John Wiley and Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD000011.pub3;
18. Hogg R.S., Heath K., Bangsberg D., Yip B., Press N., O'Shaughnessy M.V., and Montaner J.S. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16 (2002) 1051-1058
19. Kagay C.R., Porco T.C., Liechty C.A., Charlebois E., Clark R., Guzman D., Moss A.R., and Bangsberg D.R. Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. Clin. Infect. Dis. 38 Suppl 5 (2004) S414-S420
20. Keiser P., Nassar N., Kvanli M.B., Turner D., Smith J.W., and Skiest D. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J. Acq. Immune Def. Synd. 27 (2001) 14-19
21. Lanzafame M., Trevenzoli M., Cattelan A.M., Rovere P., and Parrinello A. Directly observed therapy in HIV therapy: A realistic perspective?. J. Acq. Immune Def. Synd. 25 (2000) 200-201
22. Leibowitz A.A., and Sood N. Market power and state costs of HIV/AIDS drugs. Int. J. Health Care Finance Econom. 7 (2007) 59-71
23. Lucas G.M., Cheever L.W., Chaisson R.E., and Moore R.D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J. Acq. Immune Def. Synd. 27 (2001) 251-259
24. Lucas G.M., Gebo K.A., Chaisson R.E., and Moore R.D. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 16 (2002) 767-774
25. Lucas G.M., Mullen B.A., McCaul M.E., Weidle P.J., Hader S., and Moore R.D. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS 21 (2007) 564-574
26. Luce B., Manning W., Siegel J., and Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York
27. Maggiolo F., Ravasio L., Ripamonti D., Gregis G., Quinzan G., Arici C., Airoldi M., and Suter F. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin. Infect. Dis. 40 (2005) 158-163
28. Mitty J.A., and Flanigan T.P. Community-based interventions for marginalized populations. Clin. Infect. Dis. 38 Suppl. 5 (2004) S373-S375
29. Nachega J.B., Hislop M., Dowdy D.W., Chaisson R.E., Regensberg L., and Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann. Intern. Med. 146 (2007) 564-573
30. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338 (1998) 853-860
31. Palella Jr. F.J., Deloria-Knoll M., Chmiel J.S., Moorman A.C., Wood K.C., Greenberg A.E., and Holmberg S.D. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med. 138 (2003) 620-626
32. Paterson D.L., Swindells S., Mohr J., Brester M., Vergis E.N., Squier C., Wagener M.M., and Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133 (2000) 21-30
33. Pinkerton S.D., and Holtgrave D.R. Economic impact of delaying or preventing AIDS in persons with HIV. Am. J. Manag. Care 5 (1999) 289-298
34. Poundstone K.E., Chaisson R.E., and Moore R.D. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 15 (2001) 1115-1123
35. Raboud J.M., Harris M., Rae S., and Montaner J.S. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med. 3 (2002) 118-124
36. Rigsby M.O., Rosen M.I., Beauvais J.E., Cramer J.A., Rainey P.M., O'Malley S.S., Dieckhaus K.D., and Rounsaville B.J. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J. Gen. Intern. Med. 15 (2000) 841-847
37. Schackman B.R., Finkelstein R., Neukermans C.P., Lewis L., and Eldred L. The cost of HIV medication adherence support interventions: results of a cross-site evaluation. AIDS Care 17 (2005) 927-937
38. Schackman B.R., Gebo K.A., Walensky R.P., Losina E., Muccio T., Sax P.E., Weinstein M.C., Seage III G.R., Moore R.D., and Freedberg K.A. The lifetime cost of current human immunodeficiency virus care in the United States. Med. Care 44 (2006) 990-997
39. Silverman K., Higgins S.T., Brooner R.K., Montoya I.D., Cone E.J., Schuster C.R., and Preston K.L. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch. Gen. Psychiatry 53 (1996) 409-415
40. Silverman K., Wong C.J., Higgins S.T., Brooner R.K., Montoya I.D., Contoreggi C., Umbricht-Schneiter A., Schuster C.R., and Preston K.L. Increasing opiate abstinence through voucher-based reinforcement therapy. Drug Alcohol Depend. 41 (1996) 157-165
41. Sindelar J.L., Olmstead T.A., and Peirce J.M. Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs. Addiction 102 (2007) 1463-1471
42. Snyder D.C., and Chin D.P. Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default. Am. J. Respir. Crit. Care Med. 160 (1999) 582-586
43. Sorensen J.L., Haug N.A., Delucchi K.L., Gruber V., Kletter E., Batki S.L., Tulsky J.P., Barnett P., and Hall S. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 88 (2007) 54-63
44. Tuboi S.H., Harrison L.H., Sprinz E., Albernaz R.K., and Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J. Acq. Immune Def. Synd. 40 (2005) 324-328
45. Tuldra A., and Wu A.W. Interventions to improve adherence to antiretroviral therapy. J. Acq. Immune Def. Synd. 31 Suppl. 3 (2002) S154-S157
46. Uldall K.K., Palmer N.B., Whetten K., and Mellins C. Adherence in people living with HIV/AIDS, mental illness, and chemical dependency: a review of the literature. AIDS Care 16 Suppl 1 (2004) S71-S96
47. Walensky R.P., Paltiel A.D., Losina E., Mercincavage L.M., Schackman B.R., Sax P.E., Weinstein M.C., and Freedberg K.A. The survival benefits of AIDS treatment in the United States. J. Infect. Dis. 194 (2006) 11-19
48. 9 cells/L. Ann. Intern. Med. 139 (2003) 810-816
49. Wood E., Hogg R.S., Yip B., Harrigan P.R., O'Shaughnessy M.V., and Montaner J.S. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?. AIDS 17 (2003) 711-720